5.2.4. beta-3 agonist. mechanism action: beta-3 adrenoceptors predominant beta receptors expressed smooth muscle cells detrusor stimulation thought induce detrusor relaxation. mode action beta-3 agonists fully elucidated . efficacy: mirabegron 50 mg first clinically available beta-3 agonist approval use adults oab. mirabegron undergone extensive evaluation rcts conducted europe, australia, north america, japan [228-232]. mirabegron demonstrated significant efficacy treating symptoms oab, including micturition frequency, urgency uui also patient perception treatment benefit. studies predominantly female study population. meta-analysis eight rcts including 10,248 patients (27% male) found mirabegron treatment resulted reduced frequency, urgency uui rates, well improved voided volume statistically significant improvement nocturia compared placebo tolterodine . mirabegron evaluated male patients oab context luts either associated associated bpo confirmed urodynamics . mirabegron 25 mg daily led increased satisfaction improved qol, symptoms assessed validated questionnaires (ipss oab-ss), improved non-obstructed patients. mirabegron add-on therapy studied oab patients incontinence despite antimuscarinic therapy , predominantly female study population. asian study higher proportion male subjects (approximately one third) reported superiority placebo reducing frequency micturition report results separately genders . study 1,000 patients approximately 30% male, combination therapy mirabegron 25/50 mg solifenacin 5/10 mg associated statistically significant improvements patient outcomes health related qol vs. solifenacin 5 mg placebo; however, separate effects men women . another study, 28% patients male, mirabegron significantly improved patient reported perception condition qol whether patients incontinent . phase iv study, small proportion male subjects, reported addition mirabegron people persisting urgency despite solifenacin japanese population . rct suggested mirabegron might lead improvement urinary symptoms sexual function patients suffering bpo concurrent erectile dysfunction . study showed significant improvement iief-15 total score ipss score patients treated mirabegron + doxazosin . nevertheless, multicentre rcts large numbers patients required consolidate data. tolerability safety: common treatment-related adverse events mirabegron groups hypertension, uti, headache nasopharyngitis [228-231]. mirabegron contraindicated patients severe uncontrolled hypertension (systolic blood pressure ≥ 180 mmhg diastolic blood pressure ≥ 110 mmhg, both). blood pressure measured starting treatment monitored regularly treatment. combination thirteen clinical studies including 13,396 patients, 25% male, showed oab treatments (anticholinergics mirabegron) associated increased risk hypertension cardiovascular events compared placebo . proportion patients dry mouth constipation mirabegron groups notably lower reported rcts oab agents active control tolterodine . evaluation urodynamic parameters men combined boo oab concluded mirabegron adversely affect voiding urodynamic parameters compared placebo terms qmax, detrusor pressure maximum flow bci . overall change pvr mirabegron small . small prospective study (mainly focused males) shown mirabegron 25 mg safe patients aged 80 years multiple co-morbidities . pooled analysis three trials, twelve weeks one-year trial showed, patients aged > 65 years, favourable tolerability profile mirabegron antimuscarinics . pillar phase iv study also showed large population 888 patients ≥ 65 years (approx. 30% males), mirabegron 50 mg safe effective . eighteen-week study 3,527 patients (23% male), incidence adverse events higher combination (solifenacin 5 mg plus mirabegron 25 mg) group (40%) mirabegron 25 mg alone group (32%). events recorded urinary retention low (< 1%) reported slightly frequently combined group compared monotherapy placebo groups. pvr volume slightly increased combined group compared solifenacin 5 mg, mirabegron monotherapy placebo groups. combined therapy solifenacin 5 mg plus mirabegron 25 mg solifenacin 5 mg plus mirabegron 50 mg provided improvements efficacy generally consistent additive effect . retrospective analysis persistence adherence 21,996 patients, 30% male, median time discontinuation significantly longer mirabegron (169 days) compared tolterodine (56 days) antimuscarinics (30-78 days). statistical difference men women . phase iii empowur trial comparing vibegron placebo tolterodine showed daily 75 mg vibegron provided statistically significant reductions micturitions, urgency episodes uui . treatment well tolerated favourable safety profile. however, majority study population (85%) female vibegron yet licenced europe. practical considerations: long-term studies efficacy safety mirabegron men age luts yet available. available studies mirabegron combination antimuscarinics oab patients predominantly female study population, trials still pending. summary evidencelemirabegron improves storage luts, including urinary frequency, urgency uui.2patients prescribed mirabegron remained treatment longer prescribed antimuscarinics.3 recommendationstrength ratinguse beta-3 agonists men moderate-to-severe luts mainly bladder storage symptoms.weak